皮肤鳞状细胞癌：最新综述
Cutaneous Squamous Cell Carcinoma: An Updated Review.
作者信息
Jiang Rina, Fritz Mike, Que Syril Keena T
机构信息
Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
出版信息
Cancers (Basel). 2024 May 8;16(10):1800. doi: 10.3390/cancers16101800.
Abstract
Representing the second most common skin cancer, the incidence and disease burden of cutaneous squamous cell carcinoma (cSCC) continues to increase. Surgical excision of the primary site effectively cures the majority of cSCC cases. However, an aggressive subset of cSCC persists with clinicopathological features that are indicative of higher recurrence, metastasis, and mortality risks. Acceleration of these features is driven by a combination of genetic and environmental factors. The past several years have seen remarkable progress in shaping the treatment landscape for advanced cSCC. Risk stratification and clinical management is a top priority. This review provides an overview of the current perspectives on cSCC with a focus on staging, treatment, and maintenance strategies, along with future research directions.
摘要
作为第二常见的皮肤癌，皮肤鳞状细胞癌（cSCC）的发病率和疾病负担持续上升。对原发部位进行手术切除可有效治愈大多数cSCC病例。然而，一部分侵袭性cSCC病例具有提示更高复发、转移和死亡风险的临床病理特征。这些特征的加剧是由遗传和环境因素共同驱动的。在过去几年中，晚期cSCC的治疗格局取得了显著进展。风险分层和临床管理是首要任务。本综述概述了目前对cSCC的看法，重点关注分期、治疗和维持策略以及未来的研究方向。
相似文献
1
Cutaneous Squamous Cell Carcinoma: An Updated Review.
Cancers (Basel). 2024 May 8;16(10):1800. doi: 10.3390/cancers16101800.
2
Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease.
Am J Clin Dermatol. 2016 Oct;17(5):491-508. doi: 10.1007/s40257-016-0207-3.
3
Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.
J Am Acad Dermatol. 2018 Feb;78(2):249-261. doi: 10.1016/j.jaad.2017.08.058.
4
Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging.
J Am Acad Dermatol. 2018 Feb;78(2):237-247. doi: 10.1016/j.jaad.2017.08.059.
5
Cutaneous squamous cell carcinoma staging may influence management in users: A survey study.
Cancer Med. 2022 Jan;11(1):94-103. doi: 10.1002/cam4.4426. Epub 2021 Nov 18.
6
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention.
Eur J Cancer. 2020 Mar;128:60-82. doi: 10.1016/j.ejca.2020.01.007. Epub 2020 Feb 26.
7
Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study.
JAMA Dermatol. 2018 Apr 1;154(4):428-434. doi: 10.1001/jamadermatol.2017.6428.
8
Implications of Satellitosis or In-transit Metastasis in Cutaneous Squamous Cell Carcinoma: A Prognostic Omission in Cancer Staging Systems.
JAMA Dermatol. 2022 Apr 1;158(4):390-394. doi: 10.1001/jamadermatol.2022.0001.
9
Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: A 5-year, multicenter, prospective cohort study.
J Am Acad Dermatol. 2020 Jan;82(1):139-148. doi: 10.1016/j.jaad.2019.06.1303. Epub 2019 Jul 3.
10
Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
J Drugs Dermatol. 2019 Oct 1;18(10):980-984.
引用本文的文献
1
Assessing changes in ultraviolet radiation-exposed mouse skin using optical coherence tomography.
PLoS One. 2025 Aug 11;20(8):e0328647. doi: 10.1371/journal.pone.0328647. eCollection 2025.
2
Coexistence of Lichen Planus and Squamous Cell Carcinoma on Sun-Exposed Skin: A Case Report.
Cureus. 2025 Jun 17;17(6):e86194. doi: 10.7759/cureus.86194. eCollection 2025 Jun.
3
A Comprehensive Narrative Review of the Challenges Surrounding Cutaneous SCC.
Dermatol Ther (Heidelb). 2025 Jun 23. doi: 10.1007/s13555-025-01470-7.
4
Current and Emerging Insights into the Causes, Immunopathogenesis, and Treatment of Cutaneous Squamous Cell Carcinoma.
Cancers (Basel). 2025 May 19;17(10):1702. doi: 10.3390/cancers17101702.
5
Eph/ephrin-mediated immune modulation: a potential therapeutic target.
Front Immunol. 2025 Apr 22;16:1539567. doi: 10.3389/fimmu.2025.1539567. eCollection 2025.
6
Inciting commensal human papillomavirus immunity to combat cancer.
Trends Cancer. 2025 Jul;11(7):616-618. doi: 10.1016/j.trecan.2025.04.006. Epub 2025 May 1.
7
HIPK4 accelerates cutaneous squamous cell carcinoma progression by phosphorylating TAp63 and inhibiting EFEMP1 expression.
J Biol Chem. 2025 Jul;301(7):108564. doi: 10.1016/j.jbc.2025.108564. Epub 2025 Apr 30.
8
Mutational Profile of Blood and Tumor Tissue and Biomarkers of Response to PD-1 Inhibitors in Patients with Cutaneous Squamous Cell Carcinoma.
Cancers (Basel). 2025 Mar 31;17(7):1172. doi: 10.3390/cancers17071172.
9
Genomic profiling and personalized treatment strategies for skin malignancies: findings from the center for cancer genomics and advanced therapeutics database.
Int J Clin Oncol. 2025 May;30(5):856-866. doi: 10.1007/s10147-025-02755-9. Epub 2025 Mar 29.
10
Global, regional, national prevalence, mortality, and disability-adjusted life-years of cutaneous squamous cell carcinoma and trend analysis from 1990 to 2021 and prediction to 2045.
Front Oncol. 2025 Feb 6;15:1523169. doi: 10.3389/fonc.2025.1523169. eCollection 2025.
本文引用的文献
1
Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis.
Exp Dermatol. 2024 Jan;33(1):e14978. doi: 10.1111/exd.14978. Epub 2023 Nov 16.
2
Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma.
Sci Transl Med. 2023 Oct 11;15(717):eade1844. doi: 10.1126/scitranslmed.ade1844.
3
Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec.
JAAD Case Rep. 2023 Aug 9;40:53-57. doi: 10.1016/j.jdcr.2023.07.033. eCollection 2023 Oct.
4
Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study.
J Clin Med. 2023 Jul 22;12(14):4837. doi: 10.3390/jcm12144837.
5
Comprehensive profiling identifies tumour and immune microenvironmental differences in clinical subsets of cutaneous squamous cell carcinoma.
Br J Dermatol. 2023 Oct 25;189(5):588-602. doi: 10.1093/bjd/ljad250.
6
Advances in cutaneous squamous cell carcinoma.
Nat Rev Cancer. 2023 Jul;23(7):430-449. doi: 10.1038/s41568-023-00583-5. Epub 2023 Jun 7.
7
Electrodesiccation and Curettage for Squamous Cell Carcinoma in Situ: The Effect of Anatomic Location on Local Recurrence.
Dermatol Surg. 2023 Sep 1;49(9):821-824. doi: 10.1097/DSS.0000000000003855. Epub 2023 Jun 2.
8
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Cancer Res Treat. 2023 Oct;55(4):1104-1112. doi: 10.4143/crt.2023.502. Epub 2023 May 17.
9
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
N Engl J Med. 2023 Mar 2;388(9):804-812. doi: 10.1056/NEJMoa2203086.
10
Dermatopathologic features of cutaneous squamous cell carcinoma and actinic keratosis: Consensus criteria and proposed reporting guidelines.
J Am Acad Dermatol. 2023 Jun;88(6):1317-1325. doi: 10.1016/j.jaad.2022.12.057. Epub 2023 Feb 24.
Zotero 插件